Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1866954 | 1.00 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL1862766 | 1.00 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL3616023 | 1.00 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL1862764 | 1.00 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL1862768 | 1.00 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL31375638 | 0.83 | OPRM1 (0.44) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL26649090 | 0.83 | OPRM1 (0.44) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4972107 | 0.83 | SLC6A2 (0.42) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL27758708 | 0.82 | SLC6A2 (0.45) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL973412 | 0.82 | GBA1 (0.45) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-1966139-B1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| EP-1966139-A1 | ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | SLC6A4 529/4885SLC6A2 467/4885SLC6A3 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.